Co-Diagnostics, Inc. (NASDAQ:CODX) Short Interest Down 16.7% in February

Co-Diagnostics, Inc. (NASDAQ:CODX) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 193,700 shares, a decline of 16.7% from the February 13th total of 232,600 shares. Based on an average trading volume of 207,200 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.6% of the shares of the stock are short sold.

Co-Diagnostics Stock Up 5.2 %

Co-Diagnostics stock traded up $0.02 during midday trading on Wednesday, hitting $0.46. The company’s stock had a trading volume of 432,952 shares, compared to its average volume of 174,511. The stock’s 50-day moving average price is $0.67 and its 200-day moving average price is $0.94. Co-Diagnostics has a 12 month low of $0.44 and a 12 month high of $2.23. The company has a market capitalization of $14.82 million, a PE ratio of -0.34 and a beta of 1.29.

Institutional Investors Weigh In On Co-Diagnostics

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC raised its position in Co-Diagnostics by 7.5% in the fourth quarter. Geode Capital Management LLC now owns 345,511 shares of the company’s stock worth $259,000 after acquiring an additional 24,236 shares in the last quarter. Thompson Davis & CO. Inc. raised its position in Co-Diagnostics by 37.8% in the fourth quarter. Thompson Davis & CO. Inc. now owns 57,200 shares of the company’s stock worth $43,000 after acquiring an additional 15,700 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Co-Diagnostics in the third quarter worth about $55,000. 14.99% of the stock is currently owned by institutional investors.

Co-Diagnostics Company Profile

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.